"Programs like AIM are essential to not only driving startups’ innovation journey but also reinforcing UC San Diego's role as ...

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive ...

Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

From genetically modified mosquitoes to clinical therapies, learn how scientists apply gene editing techniques to answer a ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

ViGeneron GmbH, a clinical-stage gene therapy company based in Munich, Germany, shared details of two new milestones in an ...

Ambry Genetics, a leader in clinical genomic testing, today announced its contribution to a study published in Nature that significantly advances our understanding of BRCA2 gene variants. As the ...

Genome editing with CRISPR-Cas is often associated with the induction of mutations. However, a team of researchers from the ...

For the first time, barley has been sown in Switzerland that has been genetically engineered using the new CRISPR/Cas method.